Full Name
Salvatore Siena
Company / Affiliation
Grande Ospedale Metropolitano Niguarda, Milan, Italy
Speaker Bio
Salvatore Siena is Full Professor of Medical Oncology at Università degli Studi di Milano (La Statale) in Milan, Italy, where he also served as Director of the School of Specialization in Medical Oncology from 2022 to 2025. He is also Director of the Niguarda Cancer Center and Department of Hematology, Oncology, and Molecular Medicine, as well as the Head of the Falck Division of Medical Oncology at Grande Ospedale Metropolitano Niguarda in Milan. He serves as the delegate of Regione Lombardia in the Coordinamento Generale delle Reti Oncologiche (CRO) before the Ministry of Health in Rome, Italy. In the non-profit sector, he is actively involved as the President of Fondazione Oncologia Niguarda.
He earned his degree in Medicine and Surgery from Università degli Studi di Pavia and completed his post-doctoral training at Ospedale San Matteo in Pavia, Memorial Sloan-Kettering Cancer Center in New York, and Fred Hutchinson Cancer Center in Seattle.
From 1984 to 1997, he held tenured positions at Istituto Nazionale Tumori in Milan, followed by a tenure at Istituto Clinico Humanitas from 1997 to 1998. Since 1999, he has been affiliated with Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano (La Statale).
Dr. Siena is dedicated to both patient care and the advancement of novel cancer therapies. His research primarily focuses on phase I-II clinical trials targeting various epithelial tumors, particularly those affecting the digestive and respiratory systems. His work has been widely published in peer-reviewed journals, with 458 publications and 68,510 citations, resulting in an h-index of 109, as reported by Scopus. His research is supported by competitive grants from the European Community, Fondazione AIRC (Associazione Italiana Ricerca Cancro), Fondazione Oncologia Niguarda, the Ministero della Salute, and Fondazione Regionale Ricerca Biomedica (FRRB) of Regione Lombardia.
His contributions to clinical practice include:
• The mobilization and transplantation of blood stem cells (1989).
• Identifying the role of RAS and BRAF mutations in EGFR-targeted therapies (2007).
• Developing treatments for colorectal cancer and other malignancies targeting actionable alterations in EGFR, HER2, BRAF, ROS1, NTRK, and RET (2004 - present).
• Introducing strategies to sensitize primarily resistant colorectal cancers to immunotherapy (2022).
• In the NO-CUT trial demonstrated that omission of surgery in locally advanced rectal cancer achieving clinical complete remission after total neoadjuvant therapy does not compromise distant relapse-free survival and cure rates thus supporting the clinical practice of non-operative management of rectal cancer.
Since 2015, Thomson Reuters/Clarivate Analytics has recognized Salvatore Siena as one of the World’s Most Influential Scientific Minds and a Highly Cited Researcher. He serves on the scientific advisory boards of several medical biotechnology organizations.
In 2020, he was honored with the Premio AIRC Guido Venosta, presented by Sergio Mattarella, President of the Italian Republic, for his outstanding contributions to bridging preclinical research and therapy. His work has led to the development of new diagnostic techniques and treatment approaches for colorectal cancer.
He earned his degree in Medicine and Surgery from Università degli Studi di Pavia and completed his post-doctoral training at Ospedale San Matteo in Pavia, Memorial Sloan-Kettering Cancer Center in New York, and Fred Hutchinson Cancer Center in Seattle.
From 1984 to 1997, he held tenured positions at Istituto Nazionale Tumori in Milan, followed by a tenure at Istituto Clinico Humanitas from 1997 to 1998. Since 1999, he has been affiliated with Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano (La Statale).
Dr. Siena is dedicated to both patient care and the advancement of novel cancer therapies. His research primarily focuses on phase I-II clinical trials targeting various epithelial tumors, particularly those affecting the digestive and respiratory systems. His work has been widely published in peer-reviewed journals, with 458 publications and 68,510 citations, resulting in an h-index of 109, as reported by Scopus. His research is supported by competitive grants from the European Community, Fondazione AIRC (Associazione Italiana Ricerca Cancro), Fondazione Oncologia Niguarda, the Ministero della Salute, and Fondazione Regionale Ricerca Biomedica (FRRB) of Regione Lombardia.
His contributions to clinical practice include:
• The mobilization and transplantation of blood stem cells (1989).
• Identifying the role of RAS and BRAF mutations in EGFR-targeted therapies (2007).
• Developing treatments for colorectal cancer and other malignancies targeting actionable alterations in EGFR, HER2, BRAF, ROS1, NTRK, and RET (2004 - present).
• Introducing strategies to sensitize primarily resistant colorectal cancers to immunotherapy (2022).
• In the NO-CUT trial demonstrated that omission of surgery in locally advanced rectal cancer achieving clinical complete remission after total neoadjuvant therapy does not compromise distant relapse-free survival and cure rates thus supporting the clinical practice of non-operative management of rectal cancer.
Since 2015, Thomson Reuters/Clarivate Analytics has recognized Salvatore Siena as one of the World’s Most Influential Scientific Minds and a Highly Cited Researcher. He serves on the scientific advisory boards of several medical biotechnology organizations.
In 2020, he was honored with the Premio AIRC Guido Venosta, presented by Sergio Mattarella, President of the Italian Republic, for his outstanding contributions to bridging preclinical research and therapy. His work has led to the development of new diagnostic techniques and treatment approaches for colorectal cancer.
